December 26, 2012 — Covidien announced a definitive agreement to acquire CV Ingenuity. The companies expect to complete the acquisition in the first calendar quarter of 2013. Financial terms of the transaction were not disclosed. CV Ingenuity, a privately held company based in Fremont, Calif., is focused on improving patient outcomes in the treatment of peripheral arterial disease (PAD).
At RSNA 2012, GE Healthcare focused attention on next-generation products and solutions in its computed tomography (CT) and Advantage Workstation (AW) businesses with the announcement of three scanners now available — the Optima CT660 FREEdom Edition, the Optima CT540 and the Discovery CT750 HD FREEdom Edition.
The annual Transcatheter Cardiovascular Therapeutics (TCT) meeting brings many cutting-edge technologies to the forefront during its five days of clinical sessions. This is my editor’s choice of the most innovative technologies discussed during TCT 2012.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
A new device about the size of a business card could allow health care providers to test blood for insulin and other blood proteins, cholesterol, and even signs of viral or bacterial infection all at the same time — with one drop of blood. Preliminary tests of the V-chip, created by scientists at The Methodist Hospital Research Institute and MD Anderson Cancer Center, were published by Nature Communications.
Despite earlier signs that a less-invasive surgery is safer and better than “open” operations to repair potentially lethal abdominal aortic aneurysms, a clinical study led by a Johns Hopkins professor shows survival rates after four years are similar for both procedures.
December 21, 2012 — Nanostim Inc. announced the first successful implants of a leadless pacemaker in a series of 11 patients at Homolka Hospital in Prague, Czech Republic. The leadless pacemakers were implanted by Drs. Petr Neuzil, head of cardiology at Homolka Hospital, and Vivek Reddy, director of electrophysiology at Mount Sinai Hospital in New York.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
December 21, 2012 — Covidien announced the five-year results of the ClosureFast long-term European multicenter study in patients with chronic venous insufficiency (CVI). This study evaluates the five-year outcomes of a minimally invasive endovascular therapy for treatment of CVI.
At RSNA 2012, Hitachi featured its Echelon Oval 1.5T MRI system, which features the widest bore on the market at 74 cm ...
The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and the public that the anticoagulant Pradaxa (dabigatran etexilate mesylate) should not be used to prevent stroke or blood clots (major thromboembolic events) in patients with mechanical heart valves.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 20, 2012 — At the 98th annual meeting of the Radiological Society of North America (RSNA), Royal Philips Electronics continued the Imaging 2.0 journey by showcasing several new features for existing image modalities that deliver clinical benefits to customers while simultaneously answering the economic challenges clinicians face worldwide.
Covidien announced that the Solitaire FR Revascularization Device has been approved by Health Canada. The Solitaire FR device is used to restore blood flow to the brain in patients suffering from acute ischemic stroke.
December 20, 2012 — BlipCare has presented the world's first Wi-Fi blood pressure monitor on international crowd funding site Indiegogo.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
December 19, 2012 — The first patient has been enrolled in the Boston Scientific EVOLVE II clinical trial, which is designed to further assess the safety and effectiveness of the Synergy stent system and support U.S. Food and Drug Administration (FDA) and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.
New streamlined guidelines will help healthcare providers better treat patients with the most severe type of heart attacks, according to an American Heart Association/American College of Cardiology statement.
Merit Medical Systems Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the One Snare Endovascular Snare System.